Drug Database
TO

tolterodine (Detrol LA / Detrusitol Neo / Detrusitol Retard)

✓ Approved

Pfizer, Inc. · CHRM1 · Small Molecule

What is tolterodine?

tolterodine is a small molecule developed by Pfizer, Inc.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesDetrol LA, Detrusitol Neo, Detrusitol Retard
CompanyPfizer, Inc.
Drug ClassSmall Molecule
Molecular TargetCHRM1, CHRM2, CHRM3, CHRM4
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Pfizer, Inc.

Mechanism of Action

Molecular Targets

tolterodine acts on 4 molecular targets:

CHRM1cholinergic receptor muscarinic 1 (M1, HM1)
CHRM2cholinergic receptor muscarinic 2 (HM2)
CHRM3cholinergic receptor muscarinic 3 (HM3, PBS)
CHRM4cholinergic receptor muscarinic 4 (HM4, M4R)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

tolterodine is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Renal and urinary disordersHypertonic bladder✓ Approved
Renal and urinary disordersUrinary incontinence✓ Approved

Related Research Articles

PubMedFrontiers in cell and developmental biology2026-11-11

Antibiotic and growth factor-loaded hydrogels for infected bone defect repair: mechanisms of spatiotemporal delivery and cellular microenvironment regulation.

Chen Lin L, Zhang Xulin X, Luo Lan L, Lan Jiaping J et al.

The treatment of infected bone defects (IBDs) requires simultaneous infection control and bone regeneration. However, traditional staged treatment protocols have several limitations. These include extended treatment durations, multiple surgical procedures, and low repair efficiency. Bifunctional hydrogels loaded with antibiotics and growth factors (GFs) offer a crucial material platform for integrated treatment strategies. These hydrogels possess excellent biocompatibility, malleability, and the capacity for spatiotemporal drug delivery. This review summarizes the design principles of antibiotic- and GF-loaded hydrogels, with particular attention to sequential and synergistic release strategies and their roles in infection control, immune regulation, vascularization, and osteogenesis. Current in vitro and in vivo evaluation approaches are also discussed, together with remaining challenges in drug stability, release precision, long-term biosafety, and clinical translation. This review may provide a basis for the rational design of multifunctional hydrogel systems and their further development for infected bone defect repair.

PMID 43010935
Read full article →
PubMedNano letters2026-11-11

Nanoscale Mapping of Internal Magnetization Dynamics Reveals How Disorder Shapes Heat Generation in Magnetic Particle Hyperthermia.

Jefremovas Elizabeth M EM, Rooms Pauline P, Gallo-Córdova Álvaro Á, Morales María P MP et al.

Magnetic particle hyperthermia relies on the efficient conversion of magnetic field energy into heat, yet the microscopic mechanisms governing this process within individual particles remain poorly understood. Here, we combine AC magnetometry experiments with dynamic micromagnetic simulations to connect microstructural features, magnetization dynamics, and macroscopic heat dissipation. We resolve heat generation at the intraparticle level, uncovering heterogeneous nanoscale heat-generation bursts with nanometer and nanosecond resolution. At a given particle size, grain size acts as an experimentally tunable parameter, balancing anisotropy disorder and pinning strength, thereby controlling both the magnitude and spatiotemporal distribution of heat release. Experiments show that flux-closure-dominated nanoflower architectures composed by larger grains generate more heat than their smaller-grain counterparts, whose deeper intraparticle pinning landscape redistributes heat generation over extended time windows. Together, our results provide a mechanistic framework linking nanoparticle microstructure to magnetic heating and establish design principles for optimizing nanoflowers as magnetic hyperthermia transducers.

PMID 43012586
Read full article →
PubMedJournal of speech, language, and hearing research : JSLHR2026-11-11

Reference Data Set of Extended High-Frequency Audiometry in Young, Middle, and Older Populations.

Dorey Claire M CM, Eddins David A DA, Secor Carrie A CA, Higgins Nathan C NC et al.

Elevated thresholds in the extended high-frequency hearing range have been associated with functional hearing deficits, such as poorer speech-in-noise performance. However, unlike the standard-frequency range, there is not normative data from the International Organization for Standardization (ISO) and no recommendations from the World Health Organization (WHO) regarding a normative cutoff value for normal hearing in the extended high frequencies, limiting clinical implications for extended high-frequency threshold measurement. In the present study, we report a proposed reference data set characterizing the extended high-frequency region in 717 participants aged 18-88 years evaluated on typical clinical equipment using a methodology from both the ISO and the WHO. We hypothesized that extended high-frequency thresholds would worsen with age, show reliable test-retest inspection, and show marked elevation even in those listeners who present normal-hearing thresholds in the standard-frequency range. Sex differences were also analyzed. Audiometric thresholds were collected from 717 adult participants between the ages of 18 and 88 years (438 female, 279 male) at standard octave and interoctave frequencies between 0.25 and 16 kHz. Of those participants, 62 had repeated audiometric evaluations within 1 year of measurement. Data were analyzed using the equations reported by the 2017 ISO 7029 report and by calculating four-frequency standard and extended high-frequency (EHF) pure-tone averages (PTAs) in alignment with the WHO. Men had worse hearing than women when analyzed using a four-frequency PTA for both the standard and EHF ranges. Among participants with multiple tests within a year (n = 62), extended high-frequency threshold interclass correlation coefficients showed excellent test-retest reliability. EHF four-frequency PTAs in participants with normal hearing in the standard-frequency range had a wide range of -12.5 to 97.5 dB HL, with potential functional implications. Adaptation of norms as a single cutoff value or through the use of PTA in the EHF range is feasible due to agreement in the literature and the stability of test-retest measurements. Male extended high-frequency thresholds are poorer than the female's. EHF measurements could provide diagnostic value in outpatient clinical sessions; however, functional hearing deficits are important when considering typical versus atypical thresholds in this range. https://doi.org/10.23641/asha.34961473.

PMID 43012666
Read full article →
PubMedCell reports. Physical science2026-11-11

Ultrasound-activated drug release with extracellular vesicles.

Shi Xi X, He Weilong W, Xu Haiyue H, Dasgupta Rinki R et al.

Precise, noninvasive targeting and controlled drug release to the nervous system can transform both basic research and clinical therapy. Ultrasound combined with artificial carriers offers a promising approach for precise, noninvasive drug release. Here, we report a focused ultrasound (FUS)-responsive delivery system based on extracellular vesicles (EVs), which are naturally occurring, biocompatible phospholipid nanocarriers. To enable ultrasound responsiveness, the lipid-gas phase-transition material perfluoropentane (PFP) is co-encapsulated with therapeutic agents into EVs via low-temperature sonication. The resulting EVs are 100-200 nm in size and demonstrate efficient, on-demand release upon ultrasound stimulation. In primary cultured neurons, FUS-triggered release from EVs loaded with PFP and lidocaine suppresses neuronal activity with minimal cytotoxicity. We further demonstrate in vivo modulation of pain sensitivity in rats. Overall, this EV-based platform enables safe, ultrasound-activated drug delivery and supports therapeutic applications of lipid nanocarriers.

PMID 43011967
Read full article →
PubMedNational science review2026-11-11

Programmable multifunctional microrobots for synergistic cuproptosis-immunotherapy.

Li Chuanhua C, Li Jiaxin J, Liu Xuejia X, Chen Xuyang X et al.

Oral microrobots as drug carriers have shown great promise in enhancing the therapeutic efficacy of colorectal cancer (CRC). However, existing platforms frequently lack the programmable temporal precision required to execute complex, multistage dosing regimens. Here, we report a programmable temporal-responsive microrobot (PTRM) that autonomously navigates across the gastric acid barrier under external magnetic guidance to execute a sequential drug-release program at orthotopic tumor sites. The PTRM is engineered with a logic-gated architecture, featuring a spatially specific shell for gastric-resistant shielding and exclusive intestinal pH-triggered activation. The system's internal 'timer' is governed by the precise modulation of crosslinking densities within its dual gelatin cores, enabling finely-tuned biphasic release kinetics. Phase 1 executes the programmed release of elesclomol to induce tumor cell cuproptosis, successfully priming the tumor microenvironment by recruiting infiltrating immune cells. Following a precisely tuned 5.5 h interval, Phase 2 triggers the release of PD-1 inhibitors to activate these cells, thereby amplifying immunogenic cell death. This orchestrated sequential cytotoxicity achieved a 76% remission rate in an orthotopic CRC mouse model. Furthermore, the PTRM architecture is highly scalable, accommodating up to six-core configurations for multiphase release-establishing a versatile robotic platform for complex combinatorial therapeutic strategies against recalcitrant cancers.

PMID 43011849
Read full article →
PubMedBiomaterials science2026-11-11

Correction: Tailoring the biological performance of titanium implants via a TaCu nanocoating on MAO-porous layers: the interplay between surface topography and controlled Cu2+ release.

Yao Litao L, Tong Yuanhao Y, Lin Xiaohong X, Huang Mengmeng M et al.

Correction for 'Tailoring the biological performance of titanium implants via a TaCu nanocoating on MAO-porous layers: the interplay between surface topography and controlled Cu2+ release' by Litao Yao et al., Biomater. Sci., 2026, https://doi.org/10.1039/d6bm00600k.

PMID 43012737
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about tolterodine